Structure-based discovery and development of natural products as Type II JAK2 inhibitors for the treatment of hepatitis C

Edmond Dik Lung MA*, C. H. Leung, P. Chiu, Y. C. Cheng

*Corresponding author for this work

Research output: Contribution to journalJournal articlepeer-review

Abstract

1. Hepatitis C is a highly infectious disease that imposes a high health, social and financial burden on the population in Hong Kong and worldwide.
2. A new platform for the virtual screening of JAK2 Type II inhibitors was constructed and utilised to identify amentoflavone as a lead scaffold for the development of new inhibitors.
3. Novel natural inhibitors were developed and showed anti-JAK2 activity and anti-viral activity in cellular systems.
4. The compounds potentially represent a novel therapeutic approach to the treatment of hepatitis C, and may supplement existing regimens for hard-to-treat HCV genotypes in Hong Kong.
Original languageEnglish
Pages (from-to)S32-S36
Number of pages5
JournalHong Kong Medical Journal
Volume22
Issue number3, Suppl 4
Publication statusPublished - Jun 2016

Scopus Subject Areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Structure-based discovery and development of natural products as Type II JAK2 inhibitors for the treatment of hepatitis C'. Together they form a unique fingerprint.

Cite this